CDK2 and Cyclin E Degraders for Selective Cancer Protein Removal
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an ongoing need for effective treatments that leverage the Ubiquitin-Proteasome Pathway (UPP) to target and degrade cancer-associated proteins such as cyclin-dependent kinase 2 (CDK2) and cyclin E (CCNE1 and/or CCNE2) to address uncontrolled proliferation in cancer cells.
Innovation Solution
Development of compounds that can modulate CDK2 and/or CCNE via ubiquitination and degradation, utilizing bifunctional molecules to recruit these proteins to E3 ubiquitin ligases for proteasome-mediated degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional CDK inhibitors are used, then CDK2 activity is inhibited, but the inhibitors accumulate in cells causing toxicity and limiting therapeutic efficacy
Solution Approach 1:
The invention extracts the inhibitory function from persistent small-molecule CDK inhibitors and transfers it to transient E3 ligase recruiters. The bifunctional compounds bind CDK2 and simultaneously recruit it to E3 ligases for degradation, removing the harmful accumulation effect while maintaining therapeutic activity.
Solution Approach 2:
The invention converts the harmful effect of CDK2 overexpression into a beneficial outcome by recruiting it to E3 ligases for proteasome-mediated degradation. The same mechanism that would normally lead to harmful accumulation is redirected to achieve selective protein degradation and cell cycle arrest.
2Reliability
If CDK2 and CCNE are inhibited to stop cell cycle progression, then tumor growth is suppressed, but resistance develops through protein overexpression
Solution Approach 1:
The invention employs dynamic protein degradation rather than static inhibition. The bifunctional compounds continuously recruit CDK2 and CCNE to E3 ligases for degradation, creating a dynamic response that adapts to cellular feedback mechanisms and prevents resistance through sustained protein removal.
Solution Approach 2:
The bifunctional compounds act as intermediaries that bridge CDK2/CCNE and E3 ligases. These compounds facilitate the transfer of target proteins to degradation machinery, enabling selective removal of oncogenic proteins while bypassing conventional inhibition mechanisms that lead to resistance.
3Reliability
If selective protein degradation is achieved through E3 ligase recruitment, then cancer-associated proteins are removed, but off-target effects may occur
Solution Approach 1:
The invention applies local quality through bifunctional compounds with specific binding pockets for CDK2 and CCNE. The compounds exhibit selective affinity for these target proteins, ensuring that degradation is localized to cancer-associated proteins while sparing other cellular components.
Solution Approach 2:
The invention utilizes feedback mechanisms where the binding of bifunctional compounds to CDK2/CCNE triggers conformational changes that expose E3 ligase binding surfaces. This feedback loop ensures selective recruitment to E3 ligases only when the correct target proteins are present, minimizing off-target effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively inhibit CDK2 and CCNE signaling, offering a potential therapeutic approach to treat CDK2 and CCNE-mediated disorders by selectively degrading these proteins, thereby inhibiting cell cycle progression and tumor growth.
Implementation Method 1
modulate cyclin dependent kinase 2 (CDK2) and/or cyclin E (CCNE1 and/or CCNE2) via ubiquitination and/or degradation
Implementation Method 2
utilizing bifunctional molecules to recruit these proteins to E3 ubiquitin ligases for proteasome-mediated degradation
Data Source
AI summary
The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for degrading CDK2 and/or CCNE (CCNE1 and/or CCNE2) with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with CDK2 and/or CCNE (CCNE1 and/or CCNE2) with the compounds and compositions of the disclosure.